Search Results - "Antibodies, Monoclonal -- administration & dosage"

1

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Source: Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7

File Description: application/vnd.openxmlformats-officedocument.wordprocessingml.document

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c34416fb3adf2a299c05113cf960a2c
https://doi.org/10.1016/s1470-2045(20)30324-7

2

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Authors: Kastritis E., Palladini G., Minnema M. C., Wechalekar A. D., Jaccard A., Lee H. C., Sanchorawala V., Gibbs S., Mollee P., Venner C. P., Lu J., Schonland S., Gatt M. E., Suzuki K., Kim K., Cibeira M. T., Beksac M., Libby E., Valent J., Hungria V., Wong S. W., Rosenzweig M., Bumma N., Huart A., Dimopoulos M. A., Bhutani D., Waxman A. J., Goodman S. A., Zonder J. A., Lam S., Song K., Hansen T., Manier S., Roeloffzen W., Jamroziak K., Kwok F., Shimazaki C., Kim J. -S., Crusoe E., Ahmadi T., Tran N., Qin X., Vasey S. Y., Tromp B., Schecter J. M., Weiss B. M., Zhuang S. H., Vermeulen J., Merlini G., Comenzo R. L., Bradley Augustson, Fiona Kwok, Peter Mollee, Simon Gibbs, Chantal Doyen, Greet Bries, Isabelle Vande Broek, Ka Lung Wu, Koen Theunissen, Koen Van Eygen, Michel Delforge, Nathalie Meuleman, Philip Vlummens, Angelo Maiolino, Breno Moreno de Gusmão, Carlos Eduardo Miguel, Edvan Crusoe, Fernanda Moura, Fernanda Seguro, Jandey Bigonha, Juliane Musacchio, Karla Zanella, Laura Garcia, Marcelo Eduardo Zanella Capra, Reijane Alves de Assis, Rosane Bittencourt, Vania Hungria, Walter Braga, Wolney Barreto, Christopher Venner, Donna Reece, Emilie Lemieux-Blanchard, Kevin Song, Michael Sebag, Selay Lam, Victor Zepeda, Haitao Zhang, Jianda Hu, Jin Lu, Juan Li, Songfu Jiang, Ting Niu, Wenming Chen, Xiaonong Chen, Zhen Cai, Zhou Fude, Maja Oelholm Vase, Morten Salomo, Niels Abildgaard, Alain Fuzibet, Anne-Marie Stoppa, Arnaud Jaccard, Bertrand Arnulf, Bruno Moulin, Bruno Royer, David Ghez, Denis Caillot, Dominique Chauveau, Franck Bridoux, Lauriane Clement-Filliatre, Lionel Karlin, Lotfi Benboubker, Mamoun Dib, Margaret Macro, Mohamad Mohty, Olivier Decaux, Olivier Hermine, Olivier Tournilhac, Philippe Moreau, Salomon Manier, Sylvain Choquet, Véronique Dorvaux, Alexander Carpinteiro, Axel Nogai, Britta Besemer, Christoph Roellig, Roland Fenk, Stefan Knop, Stefan Schönland, Timon Hansen, Argiris Symeonidis, Efstathios Kastritis, Gabor Mikala, Tamás Masszi, Zsolt Nagy, Celia Suriu, Hila Magen, Iuliana Vaxman, Lev Shvidel, Meir Preis, Moshe Gatt, Noa Lavi, Osnat Jarchowsky, Tamar Tadmor, Yael Cohen, Angelo Vacca, Giovanni Palladini, Mario Boccadoro, Maurizio Martelli, Maurizio Musso, Michele Cavo, Chihiro Shimazaki, Hiroyuki Takamatsu, Kazutaka Sunami, Kenshi Suzuki, Nagaaki Katoh, Shinsuke Iida, Takayuki Ikezoe, Tomoaki Fujisaki, Yuta Katayama, Chang Ki Min, Ho-Jin Shin, Jin Seok Kim, Jung Yong Hong, Ki Hyun Kim, Sung-Soo Yoon, Aline Ramirez, Alvaro Cabrera, Christian Ramos, David Gomez Almaguer, Deborah Martinez, Guillermo Ruiz, Helen Dayani Caballero, Juan Antonio Flores Jimenez, Annemiek Broijl, Laurens Nieuwenhuizen, Monique Minnema, Paula Ypma, Wilfried Roeloffzen, Dominik Dytfeld, Grzegorz Charlinski, Grzegorz Helbig, Krzysztof Jamroziak, Sebastian Grosicki, Wieslaw Jedrzejczak, Albert Oriol Rocafiguera, Elham Askari, Fernando Escalante Barrigon, Isabel Krsnik Castello, Javier De la Rubia Comos, Jesus Martin Sanchez, Joaquin Martinez Lopez, Jose Angel Hernandez Rivas, Luis Felipe Casado Montero, Maria Jesus Blanchard Rodriguez, Maria Teresa Cibeira Lopez, Maria Victoria Mateos Manteca, Marta Sonia Gonzalez Perez, Mercedes Gironella Mesa, Rafael Rios Tamayo, Ramon Lecumberri Villamediana, Ricarda Garcia Sanchez, Sunil Lakhwani, Yolanda Gonzalez, Hareth Nahi, Kristina Carlsson, Markus Hansson, Ulf-Henrik Mellqvist, Ali Unal, Burhan Ferhanoglu, Hayri Ozsan, Levent Undar, Mehmet Turgut, Mehmet Yilmaz, Meral Beksac, Muhlis Cem Ar, Muzaffer Demir, Sevgi Besisik, Ashutosh Wechalekar, Jamie Cavenagh, Jim Cavet, Mark Cook, Rachel Hall, Adam Waxman, Anuj Mahindra, Cesar Rodriguez Valdes, Christine Ye, Craig Reeder, Daphne Friedman, David Siegel, Divaya Bhutani, Edward Libby, Eva Medvedova, Frank Passero, Giada Bianchi, Giampaolo Talamo, Guido Tricot, Hans Lee, Heather Landau, Jan Moreb, Jason Valent, Jeffrey Matous, Jeffrey A Zonder, Jesus Berdeja, Jonathan Kaufman, Keith Stockerl-Goldstein, Keren Osman, Ketan Doshi, Kevin Barton, Larry Anderson, Manisha Bhutani, Mehmet Kocoglu, Michael Rosenzweig, Michael Schuster, Michaela Liedtke, Morie Gertz, Naresh Bumma, Natalie Callander, Raymond Comenzo, Robert Vescio, Roger Pearse, Sandy W Wong, Stacey A Goodman, Stefano Tarantolo, Taimur Sher, Tibor Kovacsovics, Tomer Mark, Vaishali Sanchorawala, William Bensinger

Contributors: Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Kastritis E., Palladini G., Minnema M.C., Wechalekar A.D., Jaccard A., Lee H.C., Sanchorawala V., Gibbs S., Mollee P., Venner C.P., Lu J., Schonland S., Gatt M.E., Suzuki K., Kim K., Cibeira M.T., Beksac M., Libby E., Valent J., Hungria V., Wong S.W., Rosenzweig M., Bumma N., Huart A., Dimopoulos M.A., Bhutani D., Waxman A.J., Goodman S.A., Zonder J.A., Lam S., Song K., Hansen T., Manier S., Roeloffzen W., Jamroziak K., Kwok F., Shimazaki C., Kim J.-S., Crusoe E., Ahmadi T., Tran N., Qin X., Vasey S.Y., Tromp B., Schecter J.M., Weiss B.M., Zhuang S.H., Vermeulen J., Merlini G., Comenzo R.L., Bradley Augustson, Fiona Kwok, Peter Mollee, Simon Gibbs, Chantal Doyen, Greet Bries, Isabelle Vande Broek, Ka Lung Wu, Koen Theunissen, Koen Van Eygen, Michel Delforge, Nathalie Meuleman, Philip Vlummens, Angelo Maiolino, Breno Moreno de Gusmão, Carlos Eduardo Miguel, Edvan Crusoe, Fernanda Moura, Fernanda Seguro, Jandey Bigonha, Juliane Musacchio, Karla Zanella, Laura Garcia, Marcelo Eduardo Zanella Capra, Reijane Alves de Assis, Rosane Bittencourt, Vania Hungria, Walter Braga, Wolney Barreto, Christopher Venner, Donna Reece, Emilie Lemieux-Blanchard, Kevin Song, Michael Sebag, Selay Lam, Victor Zepeda, Haitao Zhang, Jianda Hu, Jin Lu, Juan Li, Songfu Jiang, Ting Niu, Wenming Chen, Xiaonong Chen, Zhen Cai, Zhou Fude, Maja Oelholm Vase, Morten Salomo, Niels Abildgaard, Alain Fuzibet, Anne-Marie Stoppa, Arnaud Jaccard, Bertrand Arnulf, Bruno Moulin, Bruno Royer, David Ghez, Denis Caillot, Dominique Chauveau, Franck Bridoux, Lauriane Clement-Filliatre, Lionel Karlin, Lotfi Benboubker, Mamoun Dib, Margaret Macro, Mohamad Mohty, Olivier Decaux, Olivier Hermine, Olivier Tournilhac, Philippe Moreau, Salomon Manier, Sylvain Choquet, Véronique Dorvaux, Alexander Carpinteiro, Axel Nogai, Britta Besemer, Christoph Roellig, Roland Fenk, Stefan Knop, Stefan Schönland, Timon Hansen, Argiris Symeonidis, Efstathios Kastritis, Gabor Mikala, Tamás Masszi, Zsolt Nagy, Celia Suriu, Hila Magen, Iuliana Vaxman, Lev Shvidel, Meir Preis, Moshe Gatt, Noa Lavi, Osnat Jarchowsky, Tamar Tadmor, Yael Cohen, Angelo Vacca, Giovanni Palladini, Mario Boccadoro, Maurizio Martelli, Maurizio Musso, Michele Cavo, Chihiro Shimazaki, Hiroyuki Takamatsu, Kazutaka Sunami, Kenshi Suzuki, Nagaaki Katoh, Shinsuke Iida, Takayuki Ikezoe, Tomoaki Fujisaki, Yuta Katayama, Chang Ki Min, Ho-Jin Shin, Jin Seok Kim, Jung Yong Hong, Ki Hyun Kim, Sung-Soo Yoon, Aline Ramirez, Alvaro Cabrera, Christian Ramos, David Gomez Almaguer, Deborah Martinez, Guillermo Ruiz, Helen Dayani Caballero, Juan Antonio Flores Jimenez, Annemiek Broijl, Laurens Nieuwenhuizen, Monique Minnema, Paula Ypma, Wilfried Roeloffzen, Dominik Dytfeld, Grzegorz Charlinski, Grzegorz Helbig, Krzysztof Jamroziak, Sebastian Grosicki, Wieslaw Jedrzejczak, Albert Oriol Rocafiguera, Elham Askari, Fernando Escalante Barrigon, Isabel Krsnik Castello, Javier De la Rubia Comos, Jesus Martin Sanchez, Joaquin Martinez Lopez, Jose Angel Hernandez Rivas, Luis Felipe Casado Montero, Maria Jesus Blanchard Rodriguez, Maria Teresa Cibeira Lopez, Maria Victoria Mateos Manteca, Marta Sonia Gonzalez Perez, Mercedes Gironella Mesa, Rafael Rios Tamayo, Ramon Lecumberri Villamediana, Ricarda Garcia Sanchez, Sunil Lakhwani, Yolanda Gonzalez, Hareth Nahi, Kristina Carlsson, Markus Hansson, Ulf-Henrik Mellqvist, Ali Unal, Burhan Ferhanoglu, Hayri Ozsan, Levent Undar, Mehmet Turgut, Mehmet Yilmaz, Meral Beksac, Muhlis Cem Ar, Muzaffer Demir, Sevgi Besisik, Ashutosh Wechalekar, Jamie Cavenagh, Jim Cavet, Mark Cook, Rachel Hall, Adam Waxman, Anuj Mahindra, Cesar Rodriguez Valdes, Christine Ye, Craig Reeder, Daphne Friedman, David Siegel, Divaya Bhutani, Edward Libby, Eva Medvedova, Frank Passero, Giada Bianchi, Giampaolo Talamo, Guido Tricot, Hans Lee, Heather Landau, Jan Moreb, Jason Valent, Jeffrey Matous, Jeffrey A Zonder, Jesus Berdeja, Jonathan Kaufman, Keith Stockerl-Goldstein, Keren Osman, Ketan Doshi, Kevin Barton, Larry Anderson, Manisha Bhutani, Mehmet Kocoglu, Michael Rosenzweig, Michael Schuster, Michaela Liedtke, Morie Gertz, Naresh Bumma, Natalie Callander, Raymond Comenzo, Robert Vescio, Roger Pearse, Sandy W Wong, Stacey A Goodman, Stefano Tarantolo, Taimur Sher, Tibor Kovacsovics, Tomer Mark, Vaishali Sanchorawala, William Bensinger

Source: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩
Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
New England Journal of Medicine, 385(1), 46-58. MASSACHUSETTS MEDICAL SOC

Subject Terms: [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, ComputingMilieux_MISCELLANEOUS, General Medicine, Immunoglobulin light chain, Amyloid fibril, Amyloidosis, medicine.disease, medicine, business.industry, business, Daratumumab, Immunoglobulin Light-chain Amyloidosis, Antibody, biology.protein, biology, CD38, Treatment outcome, Molecular biology, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocol, Bortezomib, Cyclophosphamide, Dexamethasone, Disease-Free Survival, Female, Human, Immunoglobulin Light-chain Amyloidosi, Male, Middle Aged, Treatment Outcome, ANTIBODY DARATUMUMAB, AL AMYLOIDOSIS, DIAGNOSIS, CRITERIA, Antibodies, Monoclonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bortezomib/administration & dosage, Cyclophosphamide/administration & dosage, Dexamethasone/administration & dosage, Humans, Immunoglobulin Light-chain Amyloidosis/drug therapy

File Description: STAMPA; application/octet-stream; application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b685c6c0877c79c6650b72aaec2ee26
https://hal.uca.fr/hal-03449529

3

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes

Authors: Luis Alberto Gómez, Gulnar Vagapova, Donal O'Shea, Terri Jerkins, Francesco Dotta, Lyle Myers, Richard Dumas, William Hagopian, Celestino Neves, Gholamreza Bonabi, Tina Vilsbøll, Simon Heller, Hilla Knobler, Johnna D Wesley, Hamish Courtney, Liubov Sokolova, S. John Weisnagel, Peter A. Senior, David Thompson, Shenaz Ramtoola, Rosa Maria Príncipe, Patrice Perron, Adie Viljoen, Mercè Fernández, Claus Bogh Juhl, Petro Kuskalo, Michael Magnotti, Monika Lukaszewicz, Amer Al-Karadsheh, Sunil Nair, Stephen C. Bain, Lidiya Belousova, Trevisan Roberto, Olinda Marques, Janne Hukkanen, Bernhard Ludvik, Mikael Rydén, Carmen De la Cuesta, Jesper Ole Clausen, Thomas R. Pieber, Frederik F Kreiner, Juan Francisco Merino, Andrew B Johnson, Matthias von Herrath, Johan Jendle, Mercedes Rigla, Moshe Phillip, Irina Ipatko, Karin Filipsson, Sumana Gangi, Jeppe Gram, Patrick English, Ofri Mosenzon, Andrey Peskov, Tetiana Zlova, Francisco J. Tinahones, Irina Dvoryashina, Natalia Krasnopeeva, C De Block, Albina Golovach, James Shaw, Loren Grossman, Seamus Sreenan, B Keymeulen, Maryna Vlasenko, Jean M. Dostou, Julio Wainstein, Björn Eliasson, George Tsoukas, Elena Frolova, Bruce W. Bode, Susana Heitor, Stine Segel, P Narendran, Hanne L. Gulseth, Bernt Johan von Scholten, Borys Mankovsky, Jorma Lahtela, Samer Nakhle, Cristina Roque, Chantal Mathieu, John G. Cooper, Christoph F Ebenbichler, Pier Marco Piatti, R. D Leslie, Cristobal Morales, Marina Kunitsyna, Bogumił Wolnik, Janusz Gumprecht, Timothy O'Brien, Leo Niskanen, Robyn L. Houlden, Ewa Pankowska, Isabel Manita, Leylya Gaysina, Agostino Gnasso, R Prager, Troels Krarup Hansen, Marina Sergeeva-Kondrachenko, Jennifer Marks, L Ruyatkina, Richard E. Pratley, Rafael Simó, Bernhard Paulweber, Peter A. Gottlieb, Galyna Myshanych, Thomas Ransom, Colin M. Dayan, Jeremy Pettus, Ken Coppieters, Iurii Lymar, Nick Oliver, Vincent Woo

Contributors: Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, Diabetes Clinic, HUS Abdominal Center, Endokrinologian yksikkö, Department of Medicine, HYKS erva, Päijät-Häme Welfare Consortium

Source: von Herrath, M, Bain, S C, Bode, B, Clausen, J O, Coppieters, K, Gaysina, L, Gumprecht, J, Hansen, T K, Mathieu, C, Morales, C, Mosenzon, O, Segel, S, Tsoukas, G, Pieber, T R & Anti-IL-21–liraglutide Study Group investigators and contributors 2021, ' Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial ', The Lancet Diabetes & Endocrinology, vol. 9, no. 4, pp. 212-224 . https://doi.org/10.1016/S2213-8587(21)00019-X

Subject Terms: Adult, Antibodies, Monoclonal/administration & dosage, B-Lymphocytes/drug effects, Diabetes Mellitus, Type 1/blood, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents/administration & dosage, Interleukins/antagonists & inhibitors, Liraglutide/administration & dosage, Male, young adult, Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine, Type 1 diabetes, medicine.disease, medicine, Placebo, Population, education.field_of_study, education, Diabetes mellitus, Diabetic ketoacidosis, Clinical trial, business.industry, business, Internal medicine, medicine.medical_specialty, Liraglutide, medicine.drug, Randomized controlled trial, law.invention, law, 3121 General medicine, internal medicine and other clinical medicine

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c355818e85babab8683c968ad3e0583
https://doi.org/10.1016/s2213-8587(21)00019-x

4

Risankizumab for pityriasis rubra pilaris

Authors: E. Brocco, E. Laffitte

Source: Clinical and experimental dermatology, Vol. 46, No 7 (2021) pp. 1322-1324

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179321a2a1d09232c2180a8677bda8e1
https://archive-ouverte.unige.ch/unige:159812

5

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Source: Facon, T, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O’Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Attal, M, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Chiu, C, Wang, J, Rampelbergh, R V, Uhlar, C M, Kobos, R, Qi, M, Usmani, S Z, MAIA Trial Investigators & Abildgaard, N 2019, ' Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma ', New England Journal of Medicine, vol. 380, no. 22, pp. 2104-2115 . https://doi.org/10.1056/NEJMoa1817249

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ab3633dfb860f2b0cd95f9e39f460d
https://doi.org/10.1056/nejmoa1817249

6

Daratumumab for systemic AL amyloidosis

Authors: Christoph Kimmich, Stefan Wörner, Carsten Müller-Tidow, Hartmut Goldschmidt, Axel Benner, Kaya Veelken, Timon Hansen, Stefan Schönland, Dirk Hose, Tobias Dittrich, Alexander Carpinteiro, Ute Hegenbart, Tobias Terzer, Jörg Beimler, Anja Seckinger, Anna Jauch

Contributors: Hematology, Basic (bio-) Medical Sciences

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf74ef2016e119f5d5ffa6dd43f5f99
https://hdl.handle.net/20.500.14017/e1c758b3-d078-4f24-b40c-59e8c7e6395d

7

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Authors: Anna Durigova, Alice Cuenant, Marie Alexandre, Caroline Mollevi, Marie Vinches, Nadia Hayaoui, Luca Gianni, Krisztian Homicsko, Marie Viala, Céline Gongora, Diego Tosi

Contributors: CRLCC Val d'Aurelle - Paul Lamarque, Hôpitaux Universitaires de Genève (HUG), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), IRCCS San Raffaele Scientific Institute [Milan, Italie], Département d'oncologie Médicale, Institut du Cancer de Montpellier (ICM), UNICANCER - Institut régional du Cancer [Montpellier] (ICM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Medical Oncology 1, Istituto dei Tumori di Milano

Source: British Journal of Cancer
British journal of cancer, vol. 118, no. 5, pp. 679-697
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩

Subject Terms: Translational Therapeutics, mAbs, first-in-human trials, non first-in-human trials, recommended dose, maximum administered dose, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/therapeutic use, Clinical Decision-Making, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dose-Response Relationship, Drug, Humans, Neoplasms/drug therapy, Research Design, Cancer Research, Oncology, Clinical decision making, First in human, Monoclonal antibody, medicine.drug_class, medicine, Dose selection, Pharmacology, Toxicity, business.industry, business, MESH: Antibodies, Monoclonal, MESH: Antineoplastic Agents, MESH: Clinical Decision-Making, MESH: Clinical Trials, Phase II as Topic, MESH: Clinical Trials, Phase III as Topic, MESH: Dose-Response Relationship, Drug, MESH: Humans, MESH: Neoplasms, MESH: Research Design, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03f0a204474d74cee7ad53b33df4109
http://europepmc.org/articles/PMC5846071

8

Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden

Authors: Stefanie Pederiva, Davide Rossi, Bernhard Gerber, Erika Lerch, Guido Ghilardi, Clemens Caspar, Sofie Brouwers, Harald Seeger, Markus G. Manz, Raphael Heimgartner, Rahel Schwotzer, Thomas Fehr, Elena Bianchi, Georg Stussi, Christine Waibel, Andreas J. Flammer

Contributors: Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Clinical Pharmacy, Experimental Pharmacology, University of Zurich, Schwotzer, Rahel

Subject Terms: Adult, Aged, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents, Immunological/administration & dosage, Bone Marrow/metabolism, Drug Resistance, Neoplasm, Female, Humans, Immunoglobulin Light-chain Amyloidosis/diagnosis, Infections/etiology, Lymphocyte Count, Male, Middle Aged, Plasma Cells/pathology, Recurrence, Retreatment, Severity of Illness Index, Treatment Outcome, 610 Medicine & health, 10032 Clinic for Oncology and Hematology, 10035 Clinic for Nephrology, 10209 Clinic for Cardiology, 2720 Hematology, 2730 Oncology, 1306 Cancer Research, Cancer Research, Oncology, Hematology, General Medicine, Internal medicine, medicine.medical_specialty, medicine, Lenalidomide, medicine.drug, Adverse effect, Bortezomib, Gastroenterology, AL amyloidosis, medicine.disease, Amyloidosis, Bone marrow, medicine.anatomical_structure, Daratumumab, business.industry, business, Refractory

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afce2e4f761edbd1d13b6d39b85360df
https://biblio.vub.ac.be/vubir/daratumumab-for-relapsed-or-refractory-al-amyloidosis-with-high-plasma-cell-burden(6968da7f-6210-4f26-88e7-74d40a0281ea).html

9

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

Contributors: İç Hastalıkları

Source: NEW ENGLAND JOURNAL OF MEDICINE
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
The New England journal of medicine, vol. 378, no. 20, pp. 1908-1919
New England Journal of Medicine, 378(20), 1908. Massachussetts Medical Society
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
The New England Journal of Medicine, 378, 1908-1919

Subject Terms: Adolescent, Adult, Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use, Child, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Familial Mediterranean Fever/drug therapy, Female, Fever/drug therapy, Hereditary Autoinflammatory Diseases/drug therapy, Humans, Injections, Subcutaneous, Interleukin-1beta/antagonists & inhibitors, Male, Mevalonate Kinase Deficiency/drug therapy, Young Adult, Human health sciences, General & internal medicine, Sciences de la santé humaine, Médecine générale & interne, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Medicine(all), General Medicine, Hereditary Autoinflammatory Diseases, Immunology, Canakinumab, medicine.drug, medicine, Mevalonate kinase deficiency, medicine.disease, Familial Mediterranean fever, Tumor necrosis factor alpha, Hyperimmunoglobulinemia D, Recurrent fever, Interleukin-1beta, business.industry, business

File Description: application/pdf; image/pdf; text/plain

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26cdda8b1bb18e898684a11901196e1
https://hdl.handle.net/2268/233446

10

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

Authors: Lawrence F. Eichenfield, Eric L. Simpson, Mette Deleuran, Diamant Thaçi, Zhen Chen, George D. Yancopoulos, Jonathan I. Silverberg, Neil M.H. Graham, Marjolein S. de Bruin-Weller, Gianluca Pirozzi, Carlos Ferrándiz, Thomas Bieber, Regina Fölster-Holst, Lisa A. Beck, Marius Ardeleanu, Bolanle Akinlade

Source: American journal of clinical dermatology, vol 20, iss 3
Eichenfield, L F, Bieber, T, Beck, L A, Simpson, E L, Thaçi, D, de Bruin-Weller, M, Deleuran, M, Silverberg, J I, Ferrandiz, C, Fölster-Holst, R, Chen, Z, Graham, N M H, Pirozzi, G, Akinlade, B, Yancopoulos, G D & Ardeleanu, M 2019, ' Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis ', American Journal of Clinical Dermatology, vol. 20, no. 3, pp. 443-456 . https://doi.org/10.1007/s40257-019-00445-7
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
American Journal of Clinical Dermatology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Subject Terms: Humans, Skin Diseases, Infectious, Dermatitis, Atopic, Antibodies, Monoclonal, Placebos, Treatment Outcome, Injections, Subcutaneous, Severity of Illness Index, Incidence, Double-Blind Method, Adult, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Phase III as Topic, Humanized, Clinical Sciences, Dermatology & Venereal Diseases, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/administration & dosage, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dermatitis, Atopic/complications, Injections, Subcutaneous, Placebos/administration & dosage, Skin Diseases, Infectious/epidemiology, Antibodies, Monoclonal, Dermatitis, Atopic, Skin Diseases, Infectious, Dermatology, General Medicine, Medicine, business.industry, business, Placebo, Internal medicine, medicine.medical_specialty, Atopic dermatitis, medicine.disease, Dupilumab, Asthma, Pharmacotherapy, Eczema herpeticum, Skin infection, Relative risk, Original Research Article

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878f5fdd0301a399436c327054e17d29
https://escholarship.org/uc/item/6xc3r0r5

11

Emerging patient-specific treatment modalities in head and neck cancer - a systematic review

Authors: Elicin, O., Cihoric, N., Vlaskou Badra, E., Ozsahin, M.

Source: Expert opinion on investigational drugs, vol. 28, no. 4, pp. 365-376

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=od______1900::e2008e79282ca908c3f45cd3c1d13431
https://serval.unil.ch/resource/serval:BIB_2709C035C3A9.P001/REF.pdf

12

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis

Authors: Michael John Nissen, Burkhard Möller, Almut Scherer, Giorgio Tamborrini, Adrian Ciurea, Monika Hebeisen, Pascale Exer, Pascal Zufferey, Raphael Micheroli

Contributors: University of Zurich, Ciurea, Adrian

Source: PLoS ONE
PloS one, vol. 14, no. 5, pp. e0216746
PLoS ONE, Vol 14, Iss 5, p e0216746 (2019)
Hebeisen, Monika; Scherer, Almut; Micheroli, Raphael; Nissen, Michael J; Tamborrini, Giorgio; Möller, Burkhard; Zufferey, Pascal; Exer, Pascale; Ciurea, Adrian (2019). Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS ONE, 14(5), e0216746. Public Library of Science 10.1371/journal.pone.0216746 <http://dx.doi.org/10.1371/journal.pone.0216746>
PLOS ONE, Vol. 14, No 5 (2019) P. e0216746

Subject Terms: 610 Medicine & health, 10051 Rheumatology Clinic and Institute of Physical Medicine, 1300 General Biochemistry, Genetics and Molecular Biology, 1100 General Agricultural and Biological Sciences, 1000 Multidisciplinary, Research Article, Medicine and Health Sciences, Clinical Medicine, Clinical Immunology, Autoimmune Diseases, Ankylosing Spondylitis, Biology and Life Sciences, Immunology, Pharmaceutics, Drug Therapy, Pharmaceutical Processing Technology, Drug Synthesis, Physiology, Immune Physiology, Cytokines, Immune System, Innate Immune System, Developmental Biology, Molecular Development, Gastroenterology and Hepatology, Inflammatory Bowel Disease, Biochemistry, Proteins, C-Reactive Proteins, Cell Biology, Cellular Types, Animal Cells, Blood Cells, White Blood Cells, Immune Cells, Oncology, Cancer Treatment, musculoskeletal diseases, Adalimumab/administration & dosage, Adult, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antibodies, Monoclonal/administration & dosage, Antirheumatic Agents/administration & dosage, Etanercept/administration & dosage, Female, Humans, Infliximab/administration & dosage, Male, Middle Aged, Spondylarthritis/drug therapy, Time Factors, Tumor Necrosis Factor Inhibitors/administration & dosage, Medicine, Science, 570 Life sciences, biology, Multidisciplinary, Infliximab, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Etanercept, Hazard ratio, Adalimumab, Golimumab, Ankylosing spondylitis, medicine.disease, Proportional hazards model, business.industry, business, TNF inhibitor, medicine.medical_treatment, ddc:616

File Description: pone.0216746.pdf - application/pdf; application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208a397e0780c903991f23ed688df78f
https://www.zora.uzh.ch/id/eprint/171473/

13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Contributors: Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Gustave Roussy (IGR), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER

Source: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (24), pp.2342-2350. ⟨10.1056/NEJMoa1809697⟩
The New England Journal of Medicine, 379, 2342-2350

Subject Terms: [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.CAN]Life Sciences [q-bio]/Cancer, PACIFIC Investigators, General Medicine, Chemoradiotherapy, Medicine, business.industry, business, Hazard ratio, Randomization, Randomized controlled trial, law.invention, law, Durvalumab, Placebo, Internal medicine, medicine.medical_specialty, Survival rate, Intention-to-treat analysis, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/administration & dosage/adverse effects, Antineoplastic Agents, Immunological/administration & dosage/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/radiotherapy, Female, Humans, Infusions, Intravenous, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Neoplasms/drug therapy/mortality/radiotherapy, Male, Middle Aged, Survival Rate, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

File Description: Print-Electronic

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::591a92a2e05c176465dfb2797c0e7222
https://hal.umontpellier.fr/hal-02284390

14

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

Authors: Paul W. H. I. Parren, Patricia Pérez-Galán, Parul Doshi, Dolors Colomer, Eva Giné, Adrian Wiestner, Heleia Roca-Ho, Armando López-Guillermo, Elias Campo, Anna Vidal-Crespo, Julio Delgado, Gaël Roué, Pablo Menendez, Neus Villamor, Jeroen J. Lammerts van Bueren, Vanina Rodriguez, Alba Matas-Céspedes

Source: Clinical Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Matas-Céspedes, A, Vidal-Crespo, A, Rodriguez, V, Villamor, N, Delgado, J, Giné, E, Roca-Ho, H, Menéndez, P, Campo, E, López-Guillermo, A, Colomer, D, Roué, G, Wiestner, A, Parren, P W H I, Doshi, P, Van Bueren, J L & Pérez-Galán, P 2017, ' The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia ', Clinical Cancer Research, vol. 23, no. 6, pp. 1493-1505 . https://doi.org/10.1158/1078-0432.CCR-15-2095

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7fb945fd1ea87f326f17934ad908f73
https://doi.org/10.1158/1078-0432.ccr-15-2095

15

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

Authors: Peter M. Voorhees, Imran Khan, Tahamtan Ahmadi, Torben Plesner, Xu Steven Xu, Kevin Liu, Xiaoyu Yan, Honghui Zhou, Pamela L. Clemens, Thomas A. Puchalski, Sagar Lonial, Richard Jansson, Juan Jose Perez Ruixo, Henk M. Lokhorst

Source: Clinical Pharmacology and Therapeutics
Xu, X S, Yan, X, Puchalski, T, Lonial, S, Lokhorst, H M, Voorhees, P M, Plesner, T, Liu, K, Khan, I, Jansson, R, Ahmadi, T, Perez Ruixo, J J, Zhou, H & Clemens, P L 2017, ' Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma ', Clinical Pharmacology & Therapeutics, vol. 101, no. 6, pp. 721-724 . https://doi.org/10.1002/cpt.577

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bff59287481cda9b2f8324c23cb392d2
https://doi.org/10.1002/cpt.577

16

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Source: Dimopoulos, M A, Oriol, A, Nahi, H, San-Miguel, J, Bahlis, N J, Usmani, S Z, Rabin, N, Orlowski, R Z, Komarnicki, M, Suzuki, K, Plesner, T, Yoon, S-S, Ben Yehuda, D, Richardson, P G, Goldschmidt, H, Reece, D, Lisby, S, Khokhar, N Z, O'Rourke, L, Chiu, C, Qin, X, Guckert, M, Ahmadi, T, Moreau, P & POLLUX Investigators 2016, ' Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma ', The New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331 . https://doi.org/10.1056/NEJMoa1607751

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61628e9bf3047e8da229f84c6cb1962
https://doi.org/10.1056/nejmoa1607751

17

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Authors: Paul G. Richardson, Huaibao Feng, Sagar Lonial, Ajai Chari, Nizar J. Bahlis, Amy Axel, Imran Khan, Henk M. Lokhorst, Peter M. Voorhees, Clarissa M. Uhlar, Saad Z. Usmani, Brendan M. Weiss, Tahamtan Ahmadi, Jianping Wang, Torben Plesner, Andrew Belch, Hareth Nahi, A. Kate Sasser

Contributors: Hematology, CCA - Clinical Therapy Development

Source: Blood, 128(1), 37-44. American Society of Hematology
Usmani, S Z, Weiss, B M, Plesner, T, Bahlis, N J, Belch, A, Lonial, S, Lokhorst, H M, Voorhees, P M, Richardson, P G, Chari, A, Sasser, A K, Axel, A, Feng, H, Uhlar, C M, Wang, J, Khan, I, Ahmadi, T & Nahi, H 2016, ' Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma ', Blood, vol. 128, no. 1, pp. 37-44 . https://doi.org/10.1182/blood-2016-03-705210

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f295fc13f374ff3f19aa41f321afe70c

18

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Contributors: Hematology, CCA - Clinical Therapy Development, Moreau, Philippe, van de Donk, Niels W. C. J, San Miguel, Jesu, Lokhorst, Henk, Nahi, Hareth, Ben Yehuda, Dina, Cavo, Michele, Cook, Gordon, Delforge, Michel, Einsele, Hermann, Zweegman, Sonja, Ludwig, Heinz, Driessen, Christoph, Palumbo, Antonio, Facon, Thierry, Plesner, Torben, Dimopoulos, Meletio, Sondergeld, Pia, Sonneveld, Pieter, Mateos, María Victoria

Source: Drugs, 76(8), 853-867. Adis International Ltd
Moreau, P, van de Donk, N W C J, Miguel, J S, Lokhorst, H, Nahi, H, Ben-Yehuda, D, Cavo, M, Cook, G, Delforge, M, Einsele, H, Zweegman, S, Ludwig, H, Driessen, C, Palumbo, A, Facon, T, Plesner, T, Dimopoulos, M, Sondergeld, P, Sonneveld, P & Mateos, M-V 2016, ' Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma ', Drugs, vol. 76, no. 8, pp. 853-867 . https://doi.org/10.1007/s40265-016-0573-4
Drugs, 76(8), 853-867. Adis
Moreau, P, van de Donk, N W C J, San Miguel, J, Lokhorst, H, Nahi, H, Ben-Yehuda, D, Cavo, M, Cook, G, Delforge, M, Einsele, H, Zweegman, S, Ludwig, H, Driessen, C, Palumbo, A, Facon, T, Plesner, T, Dimopoulos, M, Sondergeld, P, Sonneveld, P & Mateos, M-V 2016, ' Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma ', Drugs, vol. 76, no. 8, pp. 853-867 . https://doi.org/10.1007/s40265-016-0573-4

File Description: STAMPA

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::140b4ed476b5cf90b9fbd3cddfe22c43

19

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Authors: Heike Richly, Christoph Rohde, Karl Dhaene, Magdalena Jadwiga Utsch, Ugur Sahin, Özlem Türeci, Markus Jerling, Tobias Dechow, Stefan Bauer, Christoph Huber, Anna Krilova, Martin Schuler

Contributors: Supporting clinical sciences, Experimental Pathology

Subject Terms: Medizin, Aged, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents, Immunological/administration & dosage, Disease Progression, Drug Dosage Calculations, Esophageal Neoplasms/drug therapy, Esophagogastric Junction/drug effects, Female, Germany, Humans, Infusions, Intravenous, Latvia, Male, Maximum Tolerated Dose, Middle Aged, Stomach Neoplasms/drug therapy, Time Factors, Treatment Outcome, Cancer Research, Oncology, Internal medicine, medicine.medical_specialty, medicine, Response Evaluation Criteria in Solid Tumors, Gastroenterology, Immunotherapy, medicine.medical_treatment, Toxicity, Adverse effect, Tolerability, Pharmacokinetics, business.industry, business, Progressive disease, medicine.disease, Cancer

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb9949f013111d7e7dd98d889459c98
https://www.ncbi.nlm.nih.gov/pubmed/29936063

20

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Contributors: UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Clinical sciences, Hematology, Mateos, María-Victoria, Dimopoulos, Meletios A, Cavo, Michele, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Kaplan, Polina, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna M, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Chiu, Christopher, Wang, Jianping, Carson, Robin, Crist, Wendy, Deraedt, William, Nguyen, Huong, Ming, Qi, San-Miguel, Jesus for the ALCYONE Trial Investigators

Source: New England Journal of Medicine, Vol. 378, no. 6, p. 518-528 (2018)

Subject Terms: Adult, Aged, Antibodies, Monoclonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bortezomib/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Humans, Infections/chemically induced, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Melphalan/administration & dosage, Middle Aged, Multiple Myeloma/drug therapy, Prednisone/administration & dosage, Survival Rate, oncology, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Infection, Melphalan, Multiple Myeloma, Prednisone, Medicine (all), bortezomib, melphalan, prednisone, General Medicine, Medicine, business.industry, business, Survival rate, Transplantation, Internal medicine, medicine.medical_specialty, Standard treatment, Daratumumab, Oncology, Multiple myeloma, medicine.disease, medicine.drug, hemic and lymphatic diseases

File Description: ELETTRONICO

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad05469cd382ea0c0c730507710cf6c

Refine Results